(18)F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

Response rates of unselected non–small cell lung cancer (NSCLC) patients to the epidermal growth factor receptor inhibitor erlotinib are low and range from 10% to 20%. Early response assessments are needed to avoid costs and side effects of inefficient treatments. Here we determined whether early ch...

Full description

Saved in:
Bibliographic Details
Published in:J Nucl Med
Main Authors: Benz, Matthias R., Herrmann, Ken, Walter, Franziska, Garon, Edward B., Reckamp, Karen L., Figlin, Robert, Phelps, Michael E., Weber, Wolfgang A., Czernin, Johannes, Allen-Auerbach, Martin S.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5021512/
https://ncbi.nlm.nih.gov/pubmed/22045706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.111.095257
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items